GSK Will Discuss COX-2 Trial Requirements With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will meet with FDA to discuss clinical trial requirements for its Phase II dual acting COX-2 inhibitor 406381